Boston Scientific Aktie News

The medical-device company tops first-quarter sales and profit estimates.

Boston Scientific heads for two different buy zones after topping Q1 views and hoisting guidance above expectations.

Medical device maker Boston Scientific raised its annual profit forecast on Wednesday as the company banks on resilient demand for its heart devices, with post-pandemic elective surgical procedures picking up pace.

Boston Scientific Corp.'s stock BSX, +1.43% rose 2.7% early Wednesday, after the medical tech company's first-quarter earnings beat analyst estimates. The company had net income of $495 million, or 33 cents a share, for the quarter, up from $300 million, or 21 cents a share, in the year-earlier period.

MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period.

The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's device used to block blood flow during excessive bleeding or hemorrhaging as most serious.

MARLBOROUGH, Mass. , April 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF).

Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.